MaxCyte, Inc. (NASDAQ:MXCT - Get Free Report) CEO Maher Masoud purchased 100,000 shares of MaxCyte stock in a transaction that occurred on Tuesday, November 17th. The shares were acquired at an average price of $1.21 per share, for a total transaction of $121,000.00. Following the acquisition, the chief executive officer owned 575,000 shares in the company, valued at $695,750. This trade represents a 21.05% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
MaxCyte Price Performance
NASDAQ:MXCT traded up $0.08 during trading hours on Wednesday, hitting $1.25. The company had a trading volume of 969,539 shares, compared to its average volume of 1,085,091. MaxCyte, Inc. has a 52 week low of $0.64 and a 52 week high of $1.80. The stock has a 50-day moving average price of $1.25 and a 200 day moving average price of $1.07. The company has a market capitalization of $129.06 million, a PE ratio of -4.81 and a beta of 1.49.
MaxCyte (NASDAQ:MXCT - Get Free Report) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.08) by $0.03. MaxCyte had a negative return on equity of 15.05% and a negative net margin of 81.40%. The business had revenue of $8.16 million during the quarter, compared to the consensus estimate of $7.39 million. Analysts anticipate that MaxCyte, Inc. will post -0.24 EPS for the current fiscal year.
Institutional Trading of MaxCyte
Hedge funds have recently bought and sold shares of the stock. Vitruvian Partners LLP purchased a new position in MaxCyte in the second quarter worth $6,203,328. Liontrust Investment Partners LLP purchased a new stake in shares of MaxCyte during the 3rd quarter valued at $5,421,000. BlackRock Inc. purchased a new stake in shares of MaxCyte during the 2nd quarter valued at $3,765,000. Marshall Wace LLP grew its stake in MaxCyte by 54.0% during the 3rd quarter. Marshall Wace LLP now owns 1,562,275 shares of the company's stock worth $1,750,000 after buying an additional 547,497 shares during the last quarter. Finally, Brooklands Fund Management Ltd purchased a new position in MaxCyte during the 1st quarter worth $1,538,000. Hedge funds and other institutional investors own 68.81% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on the stock. Weiss Ratings downgraded shares of MaxCyte from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Wednesday, November 4th. BTIG Research reissued a "neutral" rating on shares of MaxCyte in a report on Monday, August 24th. Finally, Stifel Nicolaus set a $4.00 price target on shares of MaxCyte in a research report on Thursday, November 12th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, MaxCyte has a consensus rating of "Hold" and a consensus target price of $4.50.
Check Out Our Latest Analysis on MaxCyte
About MaxCyte
(
Get Free Report)
MaxCyte, Inc. develops and commercializes cell-engineering technology used by biotechnology and pharmaceutical companies, academic research institutions, and cell therapy developers. Its platform is designed to introduce molecules such as DNA, RNA, and proteins into cells while maintaining cell viability, supporting applications in cell therapy, gene editing, and drug discovery. The company's offerings include its Flow Electroporation systems, related consumables, and services. MaxCyte also works with cell therapy developers through licensing agreements that allow them to use its technology in developing and manufacturing therapeutic products.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MaxCyte, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.
While MaxCyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.